These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26222184)

  • 1. Focus on 16p13.3 Locus in Colon Cancer.
    Mampaey E; Fieuw A; Van Laethem T; Ferdinande L; Claes K; Ceelen W; Van Nieuwenhove Y; Pattyn P; De Man M; De Ruyck K; Van Roy N; Geboes K; Laurent S
    PLoS One; 2015; 10(7):e0131421. PubMed ID: 26222184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
    Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
    Anal Cell Pathol (Amst); 2010; 33(2):95-104. PubMed ID: 20966546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
    van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
    Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer.
    Brosens RP; Haan JC; Carvalho B; Rustenburg F; Grabsch H; Quirke P; Engel AF; Cuesta MA; Maughan N; Flens M; Meijer GA; Ylstra B
    J Pathol; 2010 Aug; 221(4):411-24. PubMed ID: 20593488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
    Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
    Cell Oncol (Dordr); 2011 Jun; 34(3):215-23. PubMed ID: 21717218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
    Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
    N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China.
    Wang LD; Qin YR; Fan ZM; Kwong D; Guan XY; Tsao GS; Sham J; Li JL; Feng XS
    Dis Esophagus; 2006; 19(6):459-67. PubMed ID: 17069589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.
    Bigagli E; De Filippo C; Castagnini C; Toti S; Acquadro F; Giudici F; Fazi M; Dolara P; Messerini L; Tonelli F; Luceri C
    Cell Oncol (Dordr); 2016 Dec; 39(6):545-558. PubMed ID: 27709558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.
    Patil MA; Gütgemann I; Zhang J; Ho C; Cheung ST; Ginzinger D; Li R; Dykema KJ; So S; Fan ST; Kakar S; Furge KA; Büttner R; Chen X
    Carcinogenesis; 2005 Dec; 26(12):2050-7. PubMed ID: 16000397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study.
    Chochi Y; Kawauchi S; Nakao M; Furuya T; Hashimoto K; Oga A; Oka M; Sasaki K
    J Pathol; 2009 Apr; 217(5):677-84. PubMed ID: 19097070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of chromosome 8q: a potential prognostic marker in resectable adenocarcinoma of the pancreas?
    Schleicher C; Poremba C; Wolters H; Schäfer KL; Senninger N; Colombo-Benkmann M
    Ann Surg Oncol; 2007 Apr; 14(4):1327-35. PubMed ID: 17235717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
    Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
    BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients.
    Conconi D; Redaelli S; Bovo G; Leone BE; Filippi E; Ambrosiani L; Cerrito MG; Grassilli E; Giovannoni R; Dalprà L; Lavitrano M
    Tumour Biol; 2016 Oct; 37(10):13831-13842. PubMed ID: 27481518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis.
    Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM
    Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis.
    Strohmeyer DM; Berger AP; Moore DH; Bartsch G; Klocker H; Carroll PR; Loening SA; Jensen RH
    Prostate; 2004 Apr; 59(1):43-58. PubMed ID: 14991865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator.
    Ogunbiyi OA; Goodfellow PJ; Herfarth K; Gagliardi G; Swanson PE; Birnbaum EH; Read TE; Fleshman JW; Kodner IJ; Moley JF
    J Clin Oncol; 1998 Feb; 16(2):427-33. PubMed ID: 9469325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS and aneusomy of chromosomes 4, 10 and 12 in colorectal carcinomas.
    Beyer K; Altendorf-Hofmann A; Chen Y; Bickel K; Petersen I
    Pathol Res Pract; 2015 Sep; 211(9):646-51. PubMed ID: 26122820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.